Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol
- Conditions
- Peripheral Artery Disease
- Interventions
- Registration Number
- NCT05635370
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
- Detailed Description
This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 10398
-
- Aged >/= 65 years on the index date
-
- Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
-
- At least two claims with peripheral artery disease diagnosis measured 365 days prior to drug initiation
-
- Prior history of dementia measured anytime prior to cohort entry date
-
- Prior history of nursing home admission in the 365 days prior to the cohort entry date
-
- Prior history of Pentoxifylline or Cilostazol use anytime prior to cohort entry date
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cilostazol Cilostazol Reference group Pentoxifylline Pentoxifylline Exposure group
- Primary Outcome Measures
Name Time Method Time to dementia onset up to 6 years Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
- Secondary Outcome Measures
Name Time Method Time to Alzheimer's disease onset up to 6 years Time to Alzheimer's disease onset. Please refer to uploaded protocol for full definition due to size limitations.
Trial Locations
- Locations (1)
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States